

# Xpeng Inc. (XPEV US)

## Mona M03, P7+'s success with 3Q24 GPM beat could make Xpeng's breakeven possible

**Upgrade to BUY.** The success of Xpeng's recent two new models, the *Mona M03* and *P7+* could help Xpeng better understand its target customers' needs and increase the chance of success for its four new models in 2025. We raise our FY25E sales volume forecast to 390,000 units accordingly. Such topline growth, along with its improving GPM, could turn Xpeng profitable in FY26E, based on our estimates.

■ **3Q24 GPM, SG&A beat.** Xpeng's 3Q24 revenue was 2% lower than our prior forecast. GPM of 15.3% in 3Q24 was 1.7ppts higher than our estimates. We attribute such beat largely to the reduction of the *P5* inventory provision and possible GPM beat from the *Mona M03*. SG&A and R&D expenses combined were about RMB280mn lower than our forecast. The loss on long-term investment of RMB216mn and the QoQ decline of RMB240mn in other income resulted in a net loss of RMB1.8bn, in line with [our prior forecast](#).

■ **Mona M03, P7+ help Xpeng find the key to sales volume driver.** Both models had a great start with attractive pricing and clear positioning. Xpeng's 4Q24 sales guidance of 87,000-91,000 units has demonstrated its improving supply chain management. More importantly, the success of these two models would help Xpeng better understand its target customers' needs and increase the chance of success for its four scheduled new models in FY25. We raise our FY25E sales volume forecast by 26% to 390,000 units with new models (including the *Mona M03* and *P7+*) making up 75% of total sales.

■ **We see early signs of profit breakeven.** Although the 3Q24 net loss and our projected 4Q24 net loss (RMB1.6bn) widened from RMB1.3-1.4bn in 1Q24 and 2Q24, we see possible narrowing of net loss in FY25E and breakeven in FY26E. We expect GPM for the *P7+* and upcoming new models to be above 10%, aided by cost reduction efforts, which could lift its FY25E GPM to 15.1%. We project SG&A and R&D combined ratio to narrow to 21% in FY25E from 32.6% in FY24E amid 78% YoY growth in revenue and stringent cost control in recent quarters. Therefore, we project net loss to narrow to RMB2.3bn in FY25E from RMB6.0bn in FY24E.

The key to our FY26E breakeven assumption still lies in sales volume growth, although the visibility for FY26E is still low. We project FY26E sales volume to be 490,000 units and we expect net profit of RMB103mn with a GPM of 15.3%.

### Earnings Summary

(YE 31 Dec)	FY22A	FY23A	FY24E	FY25E	FY26E
Revenue (RMB mn)	26,855	30,676	40,377	71,790	88,440
YoY growth (%)	28.0	14.2	31.6	77.8	23.2
Gross margin (%)	11.5	1.5	14.1	15.1	15.3
Operating profit (RMB mn)	(8,705.5)	(10,889.4)	(6,942.2)	(3,496.7)	(1,512.6)
Net profit (RMB mn)	(9,139.0)	(10,375.8)	(6,021.4)	(2,260.8)	103.1
EPS (Reported) (RMB cents)	(533.65)	(595.99)	(318.34)	(118.58)	5.36
P/S (x)	3.3	2.9	2.2	1.2	1.0
P/B (x)	2.2	2.3	2.9	3.1	3.1

Source: Company data, Bloomberg, CMBIGM estimates

**BUY (Up)**

**Target Price** US\$16.00  
 (Previous TP) US\$8.00  
**Up/Downside** 23.0%  
**Current Price** US\$13.01

#### China Auto

**Ji SHI, CFA**  
 (852) 3761 8728  
 shiji@cmbi.com.hk

**Wenjing DOU, CFA**  
 (852) 6939 4751  
 douwenjing@cmbi.com.hk

**Austin Liang**  
 (852) 3900 0856  
 austinliang@cmbi.com.hk

#### Stock Data

Mkt Cap (US\$ mn)	12,354.2
Avg 3 mths t/o (US\$ mn)	76.1
52w High/Low (US\$)	18.48/6.63
Total Issued Shares (mn)	1899.2

Source: FactSet

#### Shareholding Structure

Mr. He Xiaopeng	18.6%
Volkswagen AG	5.0%


Source: NYSE

#### Share Performance

	Absolute	Relative
1-mth	24.0%	30.8%
3-mth	80.7%	61.3%
6-mth	56.7%	56.7%

Source: FactSet

#### 12-mth Price Performance



Source: FactSet

#### Related Report

["Xpeng Inc. \(XPEV US\) - 3Q earnings preview: leading players to beat" - 15 Oct 2024](#)

["Xpeng Inc. \(XPEV US\) - Mona M03 may not be the game-changer" - 21 Aug 2024](#)

["Xpeng Inc. \(XPEV US\) - Await more details about Mona" - 22 May 2024](#)

- **Valuation/Key risks.** We upgrade our rating from Hold to **BUY** and raise our target price from US\$8.00 to US\$16.00, mainly due to its better sales outlook and early signs of profit breakeven. Our target price is based on 1.5x our revised FY25E P/S, higher than its peers. We are of the view that such valuation multiple is justified due to its possible breakeven in FY26E on our estimates. Key risks to our rating and target price include lower sales volume and/or GPM than we expect and a sector de-rating.

Figure 1: Quarterly results

RMB mn	1Q23	2Q23	3Q23	4Q23	1Q24	2Q24	3Q24	YoY	QoQ
Sales volume (units)	18,230	23,205	40,008	60,158	21,821	30,207	46,533	16.3%	54.0%
ASP (RMB)	221,252	218,173	213,195	216,936	300,082	268,527	217,087	1.8%	-19.2%
Revenue	4,033	5,063	8,530	13,050	6,548	8,111	10,102	18.4%	24.5%
Gross profit	67	(197)	(228)	809	844	1,136	1,541	N/A	35.7%
R&D expenses	(1,296)	(1,367)	(1,306)	(1,308)	(1,350)	(1,467)	(1,633)	25.1%	11.3%
SG&A expenses	(1,387)	(1,544)	(1,692)	(1,937)	(1,388)	(1,574)	(1,633)	-3.5%	3.8%
Operating profit	(2,585)	(3,090)	(3,161)	(2,053)	(1,646)	(1,609)	(1,847)	N/A	N/A
Net profit	(2,337)	(2,805)	(3,887)	(1,348)	(1,368)	(1,285)	(1,808)	N/A	N/A
Gross margin	1.7%	-3.9%	-2.7%	6.2%	12.9%	14.0%	15.3%	17.9 ppt	1.3 ppt
Operating margin	-64.1%	-61.0%	-37.1%	-15.7%	-25.1%	-19.8%	-18.3%	18.8 ppt	1.6 ppt
Net margin	-57.9%	-55.4%	-45.6%	-10.3%	-20.9%	-15.8%	-17.9%	27.7 ppt	-2.1 ppt

Source: Company data, CMBIGM

Figure 2: Earnings revision

RMB mn	New			Old			Diff (%)		
	FY24E	FY25E	FY26E	FY24E	FY25E	FY26E	FY24E	FY25E	FY26E
Revenue	40,377	71,790	88,440	41,666	60,527	71,472	-3.1%	18.6%	23.7%
Gross profit	5,708	10,848	13,502	5,412	8,030	9,785	5.5%	35.1%	38.0%
Operating profit	(6,942)	(3,497)	(1,513)	(7,508)	(6,750)	(4,815)	N/A	N/A	N/A
Net profit	(6,021)	(2,261)	103	(6,172)	(5,308)	(3,254)	N/A	N/A	N/A
Gross margin	14.1%	15.1%	15.3%	13.0%	13.3%	13.7%	1.1 ppt	1.8 ppt	1.6 ppt
Operating margin	-17.2%	-4.9%	-1.7%	-18.0%	-11.2%	-6.7%	0.8 ppt	6.3 ppt	5.0 ppt
Net margin	-14.9%	-3.1%	0.1%	-14.8%	-8.8%	-4.6%	-0.1 ppt	5.6 ppt	4.7 ppt

Source: CMBIGM estimates

Figure 3: CMBI estimates vs consensus

RMB mn	CMBIGM			Consensus			Diff (%)		
	FY24E	FY25E	FY26E	FY24E	FY25E	FY26E	FY24E	FY25E	FY26E
Revenue	40,377	71,790	88,440	41,439	66,585	85,988	-2.6%	7.8%	2.9%
Gross profit	5,708	10,848	13,502	5,604	10,044	14,571	1.9%	8.0%	-7.3%
Operating profit	(6,942)	(3,497)	(1,513)	(7,386)	(5,080)	(2,174)	N/A	N/A	N/A
Net profit	(6,021)	(2,261)	103	(5,712)	(3,502)	(479)	N/A	N/A	N/A
Gross margin	14.1%	15.1%	15.3%	13.5%	15.1%	16.9%	0.6 ppt	0.0 ppt	-1.7 ppt
Operating margin	-17.2%	-4.9%	-1.7%	-17.8%	-7.6%	-2.5%	0.6 ppt	2.8 ppt	0.8 ppt
Net margin	-14.9%	-3.1%	0.1%	-13.8%	-5.3%	-0.6%	-1.1 ppt	2.1 ppt	0.7 ppt

Source: Bloomberg, CMBIGM estimates

## Financial Summary

INCOME STATEMENT	2021A	2022A	2023A	2024E	2025E	2026E
YE 31 Dec (RMB mn)						
Revenue	20,988	26,855	30,676	40,377	71,790	88,440
Cost of goods sold	(18,366)	(23,767)	(30,225)	(34,669)	(60,941)	(74,937)
Gross profit	2,623	3,088	451	5,708	10,848	13,502
Operating expenses	(9,202)	(11,794)	(11,341)	(12,650)	(14,345)	(15,015)
SG&A expense	(5,305)	(6,688)	(6,559)	(6,750)	(8,045)	(8,715)
R&D expense	(4,114)	(5,215)	(5,277)	(6,400)	(7,000)	(7,300)
Others	218	109	495	500	700	1,000
Operating profit	(6,579)	(8,706)	(10,889)	(6,942)	(3,497)	(1,513)
Gain/loss on financial assets at FVTPL	671	84	(635)	(290)	(170)	0
Other gains/(losses)	384	(1,424)	139	100	150	150
EBITDA	(3,944)	(7,571)	(7,963)	(2,900)	1,121	3,744
Depreciation	573	915	1,646	2,028	2,311	2,584
Depreciation of ROU assets	229	379	182	258	273	283
Other amortisation	36	116	279	514	531	552
EBIT	(4,782)	(8,982)	(10,070)	(5,700)	(1,994)	326
Interest income	743	1,059	1,260	1,412	1,473	1,588
Interest expense	(55)	(132)	(269)	(322)	(267)	(204)
Pre-tax profit	(4,837)	(9,114)	(10,339)	(6,021)	(2,261)	121
Income tax	(26)	(25)	(37)	0	0	(18)
After tax profit	(4,863)	(9,139)	(10,376)	(6,021)	(2,261)	103
Others	0	0	0	0	0	0
Net profit	(4,863)	(9,139)	(10,376)	(6,021)	(2,261)	103
BALANCE SHEET	2021A	2022A	2023A	2024E	2025E	2026E
YE 31 Dec (RMB mn)						
Current assets	48,831	43,527	54,522	50,216	69,435	84,203
Cash & equivalents	11,025	14,608	21,127	14,982	23,886	28,785
Restricted cash	610	106	3,175	3,000	2,000	2,000
Account receivables	2,673	3,873	2,716	3,319	5,901	7,269
Inventories	2,662	4,521	5,526	5,224	8,348	10,265
ST bank deposits	25,858	15,349	16,812	18,000	20,000	25,000
Financial assets at FVTPL	2,834	1,262	781	591	601	611
Other current assets	3,169	3,808	4,384	5,100	8,700	10,272
Non-current assets	16,821	27,964	29,641	32,089	31,909	29,985
PP&E	5,425	10,607	10,954	10,854	10,493	9,854
Right-of-use assets	1,561	1,955	1,456	1,398	1,225	1,042
Investment in JVs & assos	1,549	2,295	2,085	1,805	1,655	1,755
Intangibles	879	1,043	4,949	4,599	4,285	3,954
Other non-current assets	7,407	12,064	10,197	13,433	14,251	13,380
Total assets	65,651	71,491	84,163	82,305	101,344	114,188
Current liabilities	18,013	24,115	36,112	38,307	58,329	69,902
Short-term borrowings	0	2,419	3,889	4,263	0	0
Account payables	12,362	14,223	22,210	25,646	45,080	55,433
Tax payable	23	28	6	40	50	50
Other current liabilities	5,254	6,954	9,640	8,021	12,906	14,163
Lease liabilities	373	491	366	337	293	257
Non-current liabilities	5,492	10,465	11,722	13,281	14,250	15,106
Long-term borrowings	1,675	4,613	5,651	6,651	6,151	5,851
Deferred income	479	694	669	1,005	1,406	1,899
Other non-current liabilities	3,338	5,158	5,403	5,625	6,693	7,356
Total liabilities	23,505	34,580	47,834	51,588	72,578	85,008
Share capital	0	0	0	0	0	0
Capital surplus	59,987	60,697	70,258	70,658	70,958	71,258
Retained earnings	(17,840)	(23,787)	(33,930)	(39,941)	(42,192)	(42,079)
Other reserves	0	0	0	0	0	0
Total shareholders equity	42,147	36,911	36,329	30,717	28,766	29,179
Total equity and liabilities	65,651	71,491	84,163	82,305	101,344	114,188

<b>CASH FLOW</b>	<b>2021A</b>	<b>2022A</b>	<b>2023A</b>	<b>2024E</b>	<b>2025E</b>	<b>2026E</b>
<b>YE 31 Dec (RMB mn)</b>						
<b>Operating</b>						
Profit before taxation	(4,837)	(9,114)	(10,339)	(6,021)	(2,261)	121
Depreciation & amortization	838	1,411	2,107	2,800	3,115	3,419
Change in working capital	3,584	(2,709)	7,352	121	11,981	6,193
Others	(679)	2,181	1,836	(189)	(422)	(749)
<b>Net cash from operations</b>	<b>(1,095)</b>	<b>(8,232)</b>	<b>956</b>	<b>(3,290)</b>	<b>12,413</b>	<b>8,984</b>
<b>Investing</b>						
Capital expenditure	(4,318)	(4,680)	(2,312)	(2,250)	(2,500)	(2,500)
Acquisition of subsidiaries/ investments	(1,033)	(619)	(699)	0	0	0
Net proceeds from disposal of short-term investments	(27,762)	9,736	2,837	(3,185)	1,000	(2,000)
Others	37	408	805	1,412	1,473	1,588
<b>Net cash from investing</b>	<b>(33,076)</b>	<b>4,846</b>	<b>631</b>	<b>(4,022)</b>	<b>(27)</b>	<b>(2,912)</b>
<b>Financing</b>						
Net borrowings	(143)	6,119	3,110	1,010	(4,263)	(1,000)
Proceeds from share issues	13,110	(2)	5,020	0	0	0
Others	1,660	(113)	(114)	(18)	(219)	(173)
<b>Net cash from financing</b>	<b>14,627</b>	<b>6,004</b>	<b>8,015</b>	<b>992</b>	<b>(4,482)</b>	<b>(1,173)</b>
<b>Net change in cash</b>						
Cash at the beginning of the year	31,542	11,635	14,714	24,302	17,982	25,886
Exchange difference	(363)	462	(15)	0	0	0
<b>Cash at the end of the year</b>	<b>11,635</b>	<b>14,714</b>	<b>24,302</b>	<b>17,982</b>	<b>25,886</b>	<b>30,785</b>
<b>GROWTH</b>	<b>2021A</b>	<b>2022A</b>	<b>2023A</b>	<b>2024E</b>	<b>2025E</b>	<b>2026E</b>
<b>YE 31 Dec</b>						
Revenue	259.1%	28.0%	14.2%	31.6%	77.8%	23.2%
Gross profit	886.0%	17.8%	(85.4%)	1,165.2%	90.1%	24.5%
EBITDA	na	na	na	na	na	234.0%
<b>PROFITABILITY</b>	<b>2021A</b>	<b>2022A</b>	<b>2023A</b>	<b>2024E</b>	<b>2025E</b>	<b>2026E</b>
<b>YE 31 Dec</b>						
Gross profit margin	12.5%	11.5%	1.5%	14.1%	15.1%	15.3%
Operating margin	(31.3%)	(32.4%)	(35.5%)	(17.2%)	(4.9%)	(1.7%)
EBITDA margin	(18.8%)	(28.2%)	(26.0%)	(7.2%)	1.6%	4.2%
Return on equity (ROE)	(12.7%)	(23.1%)	(28.3%)	(18.0%)	(7.6%)	0.4%
<b>GEARING/LIQUIDITY/ACTIVITIES</b>	<b>2021A</b>	<b>2022A</b>	<b>2023A</b>	<b>2024E</b>	<b>2025E</b>	<b>2026E</b>
<b>YE 31 Dec</b>						
Current ratio (x)	2.7	1.8	1.5	1.3	1.2	1.2
Receivable turnover days	46.5	52.6	32.3	30.0	30.0	30.0
Inventory turnover days	52.9	69.4	66.7	55.0	50.0	50.0
Payable turnover days	245.7	218.4	268.2	270.0	270.0	270.0
<b>VALUATION</b>	<b>2021A</b>	<b>2022A</b>	<b>2023A</b>	<b>2024E</b>	<b>2025E</b>	<b>2026E</b>
<b>YE 31 Dec</b>						
P/E	ns	ns	ns	ns	ns	878.4
P/E (diluted)	ns	ns	ns	ns	ns	878.4
P/B	1.8	2.2	2.3	2.9	3.1	3.1
P/CFPS	ns	ns	85.8	ns	7.2	10.1
Div yield (%)	0.0	0.0	0.0	0.0	0.0	0.0

Source: Company data, CMBIGM estimates. Note: The calculation of net cash includes financial assets.

# Disclosures & Disclaimers

## Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report. Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

## CMBIGM Ratings

**BUY** : Stock with potential return of over 15% over next 12 months  
**HOLD** : Stock with potential return of +15% to -10% over next 12 months  
**SELL** : Stock with potential loss of over 10% over next 12 months  
**NOT RATED** : Stock is not rated by CMBIGM

**OUTPERFORM** : Industry expected to outperform the relevant broad market benchmark over next 12 months  
**MARKET-PERFORM** : Industry expected to perform in-line with the relevant broad market benchmark over next 12 months  
**UNDERPERFORM** : Industry expected to underperform the relevant broad market benchmark over next 12 months

## CMB International Global Markets Limited

**Address:** 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

**CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)**

## Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM. Additional information on recommended securities is available upon request.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I) falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.") of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.